Drug Development

now browsing by category


Dr. Clay Siegall-co-founder the Seattle Genetics

Dr. Clay Siegall, Ph.D., is the co-founder of Seattle Genetics, in 1997 and has served as the company’s Chief Executive Officer since Nov. 2002 and as the president from June 2000. Siegall has a renowned experience of nearly 20 years in cancer research and therapeutic drug development. He’s trained as a scientist specialized in targeting cancer therapies. He built Seattle Genetics Foundation of scientific innovation, intensive research and drug developing practices and passion of assisting patients living with cancer. Dr. Siegall pioneered the company to attain its current leadership capacity in developing cancer antibody-drug conjugates (ADC) and retaining 2011 FDA approval. He collaborated with Takeda Pharmaceutical Company and saw ADCETRIS GROW to be a global brand that got approved in at least 65 countries. The firm also is determined to advance in the diverse network of propriety ADCs meant for treatment of cancer.

Before co-founding the company, Dr. Siegall worked with Bristol-Myers Squibb Pharmaceutical Research Institute for 6years, from 1991 to 1997 and the National Cancer Institute from 1998 to 1997. He has received multiple honors, which include 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences award, and 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year recognition. He has also authored more than 70 publications and has i5 patents. He earned Ph.D. in Genetics at George Washington University and the B.S in zoology from the University of Maryland.

Human antibodies mark the epitome of what Seattle Genetics is committed to studying, manipulate and ultimately package into drugs since it got founded in 1998. Like Lego bricks, the power of the company’s antibodies is based on the ability to connect to therapy. This antibody results to a toxic payload into cancer cell to ruin it from inside the body.

This is a Company’s criteria of rapidly catapult Seattle Genetics into the big league. It has all it takes for it to become pharmaceutical company Seattle’s biotech community is longing for-to anchor through the challenges of the cycles that have plagued the industry. And not to decamp from the manner Immunex had its operations done to get acquired by the Amgen.

Seattle Genetics has a track record of having a market value of almost $10 billion and a staff of 900 employees; the company got ranked as the largest biotech Washington. With its mega ambitions, it is aspiring to have a share of handful companies that will graduate from big pharma, it invests intensively in research and marketing and anticipates to increase more 200 employees in the firm.